Business Wire Feed
Springfield Facility Expansion Marks Key Growth Milestone for Alltrista
GREER, S.C.--(BUSINESS WIRE)--#Alltrista--Alltrista Plastics LLC (Alltrista), a subsidiary of Jadex Inc., today announced a 25,000 square-foot expansion of its Springfield, Missouri facility through a planned renovation project scheduled for completion in September 2026. This expansion more...
New Nature-Published Research Reviews How Metabolic Dysfunction May Be Core Driver in Psychiatric Diseases
Stanford’s Dr. Shebani Sethi’s Collaborative Paper on Metabolic Interventions Offers Hope for Schizophrenia, Bipolar Disorder and Serious Depression The Paper Emphasizes the Importance of Integrating Metabolic Approaches into Psychiatric Care and Explores the Relationship Between more...
LiftWell Health Announces Brand Consolidation, Board & Presidential Appointment, In-Network Expansion, and Strategic Advisory Board
Connecticut’s leading full-continuum behavioral health organization consolidates under a single brand, appoints nationally acclaimed clinician-turned-industry-builder as Board Member, President, and charts an ambitious course for expanded access to care across the state and beyond.WESTPORT, Conn.--(BUSINESS more...
Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously Published in JACC
Patients treated with tonlamarsen experienced statistically significant reductions in plasma angiotensinogen levels and clinically meaningful changes in systolic blood pressure Results support initiation of Phase 2b clinical trial of tonlamarsen in patients with acute severe more...
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed more...
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were more...
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
Hypercortisolism identified in 27.3 percent of patients with resistant hypertensionREDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and more...
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 more...
Anumana Secures FDA Clearance for First-of-Its-Kind ECG-AI Algorithm for Early Detection of Pulmonary Hypertension
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an AI-enabled software-as-a-medical-device (SaMD) that detects early signs of PH, a more...
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
– Patients with severe hypertriglyceridemia (sHTG) achieved an 83% median reduction in triglycerides (TG), with 96% of patients achieving TG levels below 500 mg/dL, a threshold associated with increased risk of acute pancreatitis – No more...
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
High treatment completion and no discontinuations due to lack of efficacy observed across faster and slower switch strategiesPRINCETON, N.J.--(BUSINESS WIRE)--$BMY #Cobenfy--Bristol Myers Squibb (NYSE: BMY) today announced data from a Phase 4 clinical trial evaluating more...
GAO Report Strengthens Case for Congressional Action on CMMI
WASHINGTON--(BUSINESS WIRE)--#congress--Today, Council for Citizens Against Government Waste (CCAGW) President Tom Schatz issued the following statement in response to a Government Accountability Office (GAO) report examining the Center for Medicare and Medicaid Innovation (CMMI): “The more...
ZIVO Bioscience Provides Special Letter to Shareholders
TROY, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (OTCQB: ZIVO), today issued the following letter to shareholders from Chairman, President and Chief Executive Officer John B. Payne. Dear Fellow Shareholders, I am writing to inform you of a more...
IVF Academy USA Launches Accelerated Program to Help OBGYNs Bring Fertility Services Into Their Practices
SAN ANTONIO, Texas--(BUSINESS WIRE)--IVF Academy USA, the rapidly growing training institution for embryologists and fertility laboratory professionals, today announced the launch of its new OBGYN Clinic-Ready Fertility Services Accelerator Program, a 30-hour hybrid training designed more...
Banner|Aetna Brings Community Together for 2026 Phoenix Heart Walk
Arizona health plan continues its longstanding support of cardiovascular research and prevention at the Phoenix Heart WalkPHOENIX--(BUSINESS WIRE)--#Aetna--Banner|Aetna, an Arizona-based health plan offering integrated coverage and care through a partnership between Banner Health and Aetna, more...
Mochi Health and Livelong Women’s Health Summit Partner to Advance Women’s Metabolic Health
The telehealth marketplace will exhibit, lead a panel on GLP-1 treatments and women's metabolic health, and host a dedicated roundtable at the April 17-18 summitSAN FRANCISCO--(BUSINESS WIRE)--Mochi Health, the telehealth marketplace transforming how patients access more...
Vida Health Redefines Metabolic Care with New Control Framework for Whole-Population Management
The clinically grounded framework replaces fragmented programs with coordinated, acuity-based care to improve outcomes and reduce healthcare spendSAN FRANCISCO--(BUSINESS WIRE)--Vida Health, a value-based, virtual cardiometabolic provider that enables patients to manage metabolic instability, today announced more...
LEO Pharma Announces New Long-Term Data for SPEVIGO® (spesolimab-sbzo) Injection in Adults with Generalized Pustular Psoriasis at AAD 2026
Long-term subcutaneous SPEVIGO® (spesolimab-sbzo) treatment reduced flare frequency in patients with generalized pustular psoriasis (GPP), with nearly 75% experiencing no flares over three years.1 Rapid flare control was observed, with 50% of patients achieving a more...
VIVAZEN® Urges Immediate Action on 7-OH as U.S. House of Representatives Examines End Needless Distribution of 7-OH Act
As Congress turns its attention to 7-OH, VIVAZEN® calls on Drug Enforcement Administration, to act promptly to schedule the synthetic lab-made drug to protect AmericansPHOENIX--(BUSINESS WIRE)--VIVAZEN®, the nation’s leading botanical wellness company, welcomed congressional scrutiny more...
FranklinCovey Provides Customized Solutions for Healthcare Organizations to Solve Key Issues: Nurse Retention and Patient Satisfaction
It’s a proven partnership model helping hospital leaders build teams that deliver extraordinary patient outcomes.SALT LAKE CITY--(BUSINESS WIRE)--#CNO--FranklinCovey (NYSE: FC), a global leadership and organizational performance partner, is providing customized solutions for healthcare organizations to more...
Jopari Solutions Expands Digital Payments Through Partnership with Zelis®
Combining Jopari’s platform with Zelis’ payment capabilities to accelerate digital medical claim payments across healthcare, with focus on property and casualtyCONCORD, Calif.--(BUSINESS WIRE)--Jopari Solutions, a provider of electronic billing and payment solutions, today announced a more...
Mapping the Mind: Feinstein Institutes Research Predicts Youth Impulsivity From Brain Structure
The findings were published in Molecular PsychiatryMANHASSET, N.Y.--(BUSINESS WIRE)--What if individual variations in brain structure could predict a young person’s tendency towards impulsive behaviors, offering early insights into mental health risks? New research from scientists more...
Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis
In the ADlong Phase 3b study*, 94% of patients achieved meaningful skin improvement (EASI-75) with up to four years of lebrikizumab treatment, reinforcing the sustained response achieved over time in patients with moderate-to-severe atopic dermatitis1. more...
Irenic Sends Letter to Teleflex Board of Directors Regarding Its Refusal to Engage with Potential Acquirors
Demands Openness to Evaluating Credible Opportunities to Maximize Shareholder Value Underscores the Company’s Sustained Value Destruction, Lack of Permanent Leadership, and Board’s Poor Alignment with Shareholders Contends Meaningful Board Change – Including a New Chair more...
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001
The Planned Multicenter Phase 1 Trial Will Evaluate STAR-001 as Monotherapy and in Combination with Spironolactone in Children with Relapsed or Refractory CNS Malignancies, Including ATRT, DIPG, GBM, Medulloblastoma, and EpendymomaDALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: more...